# Anti-viral T-cell Therapy by Gamma Capture

> **NCT06027879** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Paul Szabolcs** · enrollment: 25 (estimated)

## Conditions studied

- Adenovirus
- Cytomegalovirus Infections
- Epstein-Barr Virus Infections

## Interventions

- **BIOLOGICAL:** Specific T- Lymphocytes

## Key facts

- **NCT ID:** NCT06027879
- **Lead sponsor:** Paul Szabolcs
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-01-08
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06027879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06027879, "Anti-viral T-cell Therapy by Gamma Capture". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06027879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*